Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

As of June 30, 2016

109 joint negotiations have been **completed**** for the following drugs and indications:

Drug Product Brand Name (Generic Name)	Indication/Use *Please refer to individual jurisdictions for specific reimbursement criteria*
Abilify Maintena (aripiprazole long acting injection)	Used for the maintenance treatment of schizophrenia
Abraxane (nab-paclitaxel)	Used first-line to treat locally advanced unresectable or metastatic adenocarcinoma of the pancreas
Actemra (tocilizumab) SC	Used to treat rheumatoid arthritis
Adcetris (brentuximab)	Used to treat lymphoma
Adempas (riociguat)	Used to treat chronic thromboembolic pulmonary hypertension
Advair (salmeterol xinafoate/ fluticasone propionate)	Used to treat chronic obstructive pulmonary disease and asthma
Afinitor (everolimus)	Used to treat pancreatic neuroendocrine tumours, and to treat breast cancer
Alimta (pemetrexed)	Used to treat lung cancer (new indication)
Anoro Ellipta (umeclidinium bromide/vilanterol trifenatate)	Used to treat chronic obstructive pulmonary disease
Aptiom (eslicarbazepine)	Used to treat seizures
Aubagio (teriflunomide)	Used to treat relapsing-remitting multiple sclerosis
Avastin (bevacizumab)	Used to treat persistent, recurrent, or metastatic cervical cancer Used to treat epithelial ovarian cancer
Bosulif (bosutinib)	Used to treat chronic myelogenous leukemia (CML)
Breo Ellipta (fluticasone furoate/ vilanterol)	Used to treat chronic obstructive pulmonary disease
Brilinta (ticagrelor)†	Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome
Cimzia (certolizumab)	Used to treat ankylosing spondylitis, psoriatic arthritis
Consentyx (secukinumab)*	Used to treat moderate to severe plaque psoriasis
Diacomit (stiripentol)	Used in patients with severe myoclonic epilepsy in infancy
Dificid (fidaxomicin)	Used to treat Clostridium difficile
Duaklir Genuair (aclidinium bromide/formoterol fumarate dehydrate)	Used to treat chronic obstructive pulmonary disease (COPD)
Effient (prasugrel)	Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome
Eliquis (apixaban)	Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis
Eliquis (apixaban)	Used to treat venous thromboembolic events and prevent recurrent deep-vein thrombosis and pulmonary embolism
Erivedge (vismodegib)	Used to treat metastatic basal cell carcinoma

Drug Product Brand Name (Generic Name)	Indication/Use *Please refer to individual jurisdictions for specific reimbursement criteria*
Esbriet (pirfenidone)	Used to treat idiopathic pulmonary fibrosis
Eylea (aflibercept)	Used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and/or macular edema secondary to central retinal vein occlusion (CRVO)
Fabrazyme (agalsidase beta)	Used to treat Fabry disease
Fibristal (ulipristal acetate)	Used to treat uterine fibroids
Firazyr (icatibant)	Used to treat acute attacks of hereditary angioedema
Galexos (simeprevir)	Used to treat chronic hepatitis C Genotype 1 infection
Gazyva (obinutuzumab)	Used to treat chronic lymphocytic leukemia
Gilenya (fingolimod)†	Used to treat relapsing-remitting multiple sclerosis
Giotrif (afatinib)	Used to treat EGFR mutation positive, advanced non-small cell lung cancer
Halaven (eribulin)	Used to treat breast cancer
Harvoni (sofosbuvir/ledipsavir)	Used to treat chronic hepatitis C infection
Holkira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir)	Used to treat chronic hepatitis C infection
Ibavyr (ribavirin)	Used to treat chronic hepatitis C infection
Imbruvica (ibrutinib)	Used to treat chronic lymphocytic leukemia or small lymphocytic leukemia
Incruse Ellipta (umeclidinium)	Used to treat chronic obstructive pulmonary disease (COPD)
Inflectra (infliximab)	Used to treat rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis
Inlyta (axitinib)	Used to treat metastatic renal cell carcinoma
Inspiolto Respimat (tiotropium/olodaterol)	Used to treat chronic obstructive pulmonary disease (COPD)
Inspra (eplerenone)	Used to treat New York Heart Association (NYHA) class II systolic heart failure
Invokana (canagliflozin)	Used to treat Type 2 diabetes
Istodax (romidepsin)	Used to treat relapsed/refractory peripheral T-cell lymphoma
Jakavi (ruxolitinib)	Used to treat intermediate to high risk myelofibrosis
Janumet (sitagliptin/metformin)	Used to treat Type 2 diabetes mellitus
Januvia (sitagliptin)	Used to treat Type 2 diabetes mellitus
Jardiance (empagliflozin)	Used to treat Type 2 diabetes mellitus
Jetrea (ocriplasmin)	Used to treat symptomatic vitreomacular adhesion
Kadcyla (trastuzumab emtansine)	Used to treat HER-2 positive metastatic breast cancer
Kalydeco (ivacaftor)	Used to treat cystic fibrosis
Keytruda (pembrolizumab)	Used to treat metastatic melanoma
Kuvan (saproterin)†	Used to treat phenylketonuria
Lemtrada (alemtuzumab)	Used to treat relapsing-remitting multiple sclerosis
Lodalis (colesevelam)	Used to treat hypercholesterolemia
Mekinist (trametinib)	Used to treat metastatic melanoma
Mozobil (plerixafor)	Used in combination with *granulocyte colony-stimulating factor* to support treatment for non-Hodgkin lymphoma and multiple myeloma
Myrbetriq (mirabegron)	Used to treat overactive bladder

Drug Product Brand Name (Generic Name)	Indication/Use *Please refer to individual jurisdictions for specific reimbursement criteria*
Onbrez (indacaterol)†	Used as a bronchodilator for chronic obstructive pulmonary disease
Onglyza (saxagliptan)	Used to treat Type 2 diabetes mellitus
Oralair (grass pollen allergen extract)	Used to treat allergic rhinitis with or without conjunctivitis
Orencia (abatacept)	Used to treat rheumatoid arthritis
Perjeta (pertuzumab)	Used to treat breast cancer
Pomalyst (pomalidomide)	Used to treat multiple myeloma
Pradaxa (dabigatran)†	Used to prevent strokes in patients with atrial fibrillation
Prezcobix (darunavir/cobicistat)	Used to treat HIV-1 infection
Rebif (interferon beta-1a)	Used for clinically isolated syndrome
Remicade (infliximab)	Used to treat multiple indications including rheumatoid arthritis, ulcerative colitis and Crohn's disease
Revlimid (lenalidomide)	Used for maintenance treatment in multiple myeloma after a stem cell transplant
Seebri Breezhaler (glycopyrronium bromide)	Used to treat chronic obstructive pulmonary disease
Simbrinza (brinzolamide/brimonidine)	Used to treat glaucoma and ocular hypertension
Soliris (eculizumab)†	Used to treat paroxysmal nocturnal hemoglobinuria
Sovaldi (sofosbuvir)	Used to treat chronic hepatitis C infection
Spiriva Respimat (tiotropium)	Used to treat chronic obstructive pulmonary disease
Stivarga (regorafenib)	Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST)
Stribild (elvitegravir/cobicistat/ emtricitabine/tenofovir)	Used to treat HIV-1 infection in antiretroviral treatment-naïve adult patients
Sutent (sunitinib)	Used to treat pancreatic neuroendocrine tumours
Tafinlar (darafenib)	Used to treat metastatic melanoma
Tafinlar (dabrafenib) and Mekinist (tramatinib)	Used to treat metastatic melanoma (in combination)
Tecfidera (dimethyl fumarate)	Used to treat multiple sclerosis
Tivicay (dolutegravir)	Used to treat HIV-1 infection
Tobi Podhaler (tobramycin)	Used for the management of cystic fibrosis patients with chronic pulmonary *Pseudomonas aeruginosa* infections
Tradjenta (linagliptin) and Jentadueto (linagliptin/metformin)	Used to treat Type 2 diabetes mellitus
Treanda (bendamustine)†	Used to treat non-Hodgkin lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia
Triumeq (dolutegravir/abacavir/lamivudine)	Used to treat HIV-1 infection
Tudorza Genuair (aclidinium bromide)	Used in management of chronic obstructive pulmonary disease (COPD)
Tysabri (natalizumab)	Used to treat relapsing-remitting multiple sclerosis
Ultibro (indacaterol/glycopyrronium)	Used to treat chronic obstructive pulmonary disease
Valtrex (valacyclovir)	Used to treat specific viral infections
Votrient (pazopanib)	Used to treat metastatic renal cell carcinoma
Xalkori (crizotinib)	Used to treat advanced non-small cell lung cancer (second-line)
Xalkori (crizotinib)	Used to treat advanced non-small cell lung cancer (first-line)

Drug Product Brand Name (Generic Name)	Indication/Use *Please refer to individual jurisdictions for specific reimbursement criteria*
Xarelto (rivaroxaban)	New indication for treatment of venous thromboembolic events and prevention of recurrent deep vein thrombosis and pulmonary embolism.
Xarelto (rivaroxaban)†	Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis
Xeljanz (tofacitinib)	Used to treat rheumatoid arthritis
Xtandi (enzalutamide)	Used to treat first-line metastatic castrate resistant prostate cancer (before chemotherapy)
Xtandi (enzulatamide)	Used to treat castrate resistant prostate cancer (after chemotherapy)
Yervoy (ipilimumab)	Used for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma
Yervoy (ipilimumab)†	Used for the second-line treatment of adult patients with unresectable or metastatic melanoma
Zaxine (rifaximin)	Used to treat hepatic encephalopathy
Zydelig (idelalisib)*	Used to treat relapsed chronic lymphocytic leukemia (CLL)
Zytiga (abiraterone)	Used to treat prostate cancer
6 drug negotiations were closed as agreements were not reached:	
Byetta (exenatide)	Used to treat Type 2 diabetes
Daklinza (daclatasvir)	Used to treat chronic Hepatitis C
Opsumit (macitentan)	Used to treat pulmonary arterial hypertension
Simponi (golimumab) IV	Used to treat rheumatoid arthritis
Soliris (eculizumab)	Used to treat aHUS
Victoza (liraglutide)	Used to treat Type 2 diabetes

** A completed pan-Canadian negotiation refers to those for which a Letter of Intent (document which outlines the agreed upon terms and conditions for listing) has been signed between the lead jurisdiction for the negotiation and the manufacturer OR negotiations have been closed without a Letter of Intent.

† The initial nine products negotiated through the pCPA.

*New negotiations completed since last update of May 31, 2016.